Leave no one behind: optimizing kidney protection in type 1 diabetes
Despite unprecedented advances in the treatment of non-diabetic chronic kidney disease (CKD) and CKD in type 2 diabetes mellitus in the past decade, no new drugs have been approved for CKD in type 1 diabetes mellitus. Urgent action is needed to develop new therapies and improve outcomes for this population.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Despite unprecedented advances in the treatment of non-diabetic chronic kidney disease (CKD) and CKD in type 2 diabetes mellitus in the past decade, no new drugs have been approved for CKD in type 1 diabetes mellitus. Urgent action is needed to develop new therapies and improve outcomes for this population.
Ogle, G. D. et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th edition, and the T1D Index version 3.0. Diabetes Res. Clin. Pract. 225, 112277 (2025).